|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2001-8-15
|
|
pubmed:abstractText |
In a retrospective cohort study of salvage antiretroviral combination therapy including efavirenz, 60% of 51 patients were able to suppress HIV RNA by at least 1 log10 or to less than 50 copies/ml. A lack of the previous use of non-nucleoside reverse transcriptase inhibitors was the only factor predictive of response on multivariate analysis. No patient with a viral isolate with an increased IC50 to efavirenz by virtual phenotype had a virological response
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1581-4
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11504994-Adult,
pubmed-meshheading:11504994-Anti-HIV Agents,
pubmed-meshheading:11504994-Benzoxazines,
pubmed-meshheading:11504994-Drug Therapy, Combination,
pubmed-meshheading:11504994-HIV Infections,
pubmed-meshheading:11504994-HIV-1,
pubmed-meshheading:11504994-Humans,
pubmed-meshheading:11504994-Male,
pubmed-meshheading:11504994-Oxazines,
pubmed-meshheading:11504994-RNA, Viral,
pubmed-meshheading:11504994-Reverse Transcriptase Inhibitors,
pubmed-meshheading:11504994-Salvage Therapy,
pubmed-meshheading:11504994-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.
|
|
pubmed:affiliation |
Toronto General Hospital Immunodeficiency Clinic, University Health Network, University of Toronto, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article
|
